Christensen previously served as chief commercial officer at automated insulin delivery technology developer Insulet. He departed last week as part of a handful of executive changes at the company.
The new CEO succeeds Dr. John Dobak, who stepped down as president, CEO and board director.
“DermTech has an opportunity to transform dermatology with its revolutionary technology, strong demand and building momentum with commercial payers,” Christensen said. “Importantly, I am confident that we can improve lives and integrate our test into the melanoma care pathway. I look forward to working closely with the board and the DermTech team to drive our average selling price, grow revenue and scale our business.”
About DermTech and its new CEO
DermTech develops a non-invasive skin genomics platform to enable individualized care. It provides genomic analysis of skin samples, collected non-invasively using its Smart Stickers. This facilitates the early detection of skin cancers, while the company also develops products that assess inflamatory diseases and customize drug treatments.
Prior to joining DermTech, Christensen served as CCO at Insulet for about six years. Before that, he was GM of preventive care at Myriad Genetics. Christensen also held executive positions at Hologic and led market development teams at Cytyc Corporation.
“I’d like to welcome Bret to the team,” DermTech Chair Matt Posard said. “Bret is well positioned to lead our growing company given his significant commercial, operations and market access experience. We are confident that Bret’s demonstrated success and expertise in the diagnostics industry align with DermTech’s strategy to fully capitalize on commercializing its genomic products and executing against its many growth opportunities. The board looks forward to working with Bret and the management team to create meaningful value for stockholders.”
